US Securities Regulator Probes Illumina Over Grail Deal

The SEC has begun an investigation into Illumina's $7.1 billion acquisition of cancer detection test maker Grail, the gene sequencing company said in a regulatory filing.
Reuters Health Information

source https://www.medscape.com/s/viewarticle/995375?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost